Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Tacrolimus, ATC L04AD02 für die Zeit 01.09.2026 - 31.08.2028

Section 130a, paragraph 8 of the German Social Code, Book V (SGB V) enables health insurance funds and pharmaceutical companies to conclude framework discount agreements for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-specific, formal tendering procedures in accordance with the regulations of Part 4 of the German Act Against Restraints of Competition (GWB). For the medicines to be specified by the bidder in more detail in Annex 2 to the contract, relating to the aforementioned substance Tacrolimus, ATC L04AD02, the DAK-Gesundheit intends to conclude pharmaceutical discount agreements with as many interested pharmaceutical companies as possible until the entry into force of new pharmaceutical discount agreements. A discount contract under the authorisation model for the aforementioned substance will come into force for the first time on 01.09.2026 and will end on 31.08.2028. It will automatically end with the entry into force of the exclusive contract, regardless.